News | May 10, 2023
Boehringer Ingelheim begins clinical development for fibrotic diseases
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
The acquisition of Medisol is part of Lupin's strategy to expand its presence in the EU
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
The interaction with key Government Officials and industry leaders led to a joint exploration of possible collaboration and investments in the Healthcare ecosystem between the two countries
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Subscribe To Our Newsletter & Stay Updated
